PharmaTher Holdings (XCNQ:PHRM) Cash-to-Debt : No Debt ⁽¹⁾ (As of Feb. 2024)

View and export this data going back to 2021. Start your Free Trial

What is PharmaTher Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. PharmaTher Holdings's cash to debt ratio for the quarter that ended in Feb. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, PharmaTher Holdings could pay off its debt using the cash in hand for the quarter that ended in Feb. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for PharmaTher Holdings's Cash-to-Debt or its related term are showing as below:

XCNQ:PHRM' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 3 years, PharmaTher Holdings's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

XCNQ:PHRM's Cash-to-Debt is ranked better than
99.74% of 1540 companies
in the Biotechnology industry
Industry Median: 6.485 vs XCNQ:PHRM: No Debt

PharmaTher Holdings Cash-to-Debt Historical Data

The historical data trend for PharmaTher Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

PharmaTher Holdings Cash-to-Debt Chart

PharmaTher Holdings Annual Data

Trend

May21

May22

May23

Cash-to-Debt

No Debt

PharmaTher Holdings Quarterly Data
	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Cash-to-Debt	Get a 7-Day Free Trial										No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of PharmaTher Holdings's Cash-to-Debt

For the Biotechnology subindustry, PharmaTher Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaTher Holdings's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaTher Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where PharmaTher Holdings's Cash-to-Debt falls into.

PharmaTher Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

PharmaTher Holdings's Cash to Debt Ratio for the fiscal year that ended in May. 2023 is calculated as:

PharmaTher Holdings had no debt ⁽¹⁾.

PharmaTher Holdings's Cash to Debt Ratio for the quarter that ended in Feb. 2024 is calculated as:

PharmaTher Holdings had no debt ⁽¹⁾.

PharmaTher Holdings (XCNQ:PHRM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

PharmaTher Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of PharmaTher Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmaTher Holdings (XCNQ:PHRM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaTher Holdings Ltd (XCNQ:PHRM) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

PHRRF:USA

Address

82 Richmond Street East, Toronto, ON, CAN, M5C 1P1

Website

https://www.pharmather.com

PharmaTher Holdings Ltd is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat mental health, neurological, and pain disorders. Its product pipeline includes Ketamine, KETABET, Microneedle Patch among others.

Executives

Fabio Chianelli

Director, Senior Officer

PharmaTher Holdings (XCNQ:PHRM) Headlines

No Headlines

PharmaTher Holdings (XCNQ:PHRM) Cash-to-Debt : No Debt (1) (As of Feb. 2024)